TP53 and hepatocellular carcinoma: Since the tumor-suppressing effects of PKCδ are mediated at least in part through activating p53 transcription (Abbas et al., 2004), the existence of wild type p53 in HepG2 cells could partially explain their relatively higher sensitivity to both drugs than the other HCC cell lines which lack functional p53.